Xeris Biopharma Names John Shannon To Succeed Paul Edick As New CEO And Board Director
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire from his roles, and John P. Shannon, the current President and COO, will take over as CEO and Board Director.
July 08, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma has announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire from his roles, and John P. Shannon, the current President and COO, will take over as CEO and Board Director.
The transition to a new CEO, especially an internal candidate like John P. Shannon, is likely to be seen positively by investors as it suggests continuity and stability. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100